baclofen has been researched along with Gelineau Syndrome in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was performed to evaluate the actions of baclofen and sodium oxybate, two medications with gamma-aminobutyric acid type B (GABA(B)) receptor agonist properties, on symptoms of narcolepsy in drug-naïve teenagers." | 9.14 | Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. ( Guilleminault, C; Huang, YS, 2009) |
| "We describe five narcolepsy patients with severe excessive daytime sleepiness who had an inadequate response or experienced side effects with the initial therapies but had a positive response to treatment with baclofen." | 7.91 | Management of Excessive Daytime Sleepiness in Narcolepsy With Baclofen. ( Kelly-Pieper, K; Kothare, SV; Morse, AM, 2019) |
| "This study was performed to evaluate the actions of baclofen and sodium oxybate, two medications with gamma-aminobutyric acid type B (GABA(B)) receptor agonist properties, on symptoms of narcolepsy in drug-naïve teenagers." | 5.14 | Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. ( Guilleminault, C; Huang, YS, 2009) |
| " The aim of this paper is to provide a review of the human clinical studies of sodium oxybate and baclofen regarding sleep and the treatment of sleep disorders including narcolepsy and insomnia, as well as other disorders involving disrupted sleep such as fibromyalgia." | 4.87 | A review of sodium oxybate and baclofen in the treatment of sleep disorders. ( Brown, MA; Guilleminault, C, 2011) |
| "We describe five narcolepsy patients with severe excessive daytime sleepiness who had an inadequate response or experienced side effects with the initial therapies but had a positive response to treatment with baclofen." | 3.91 | Management of Excessive Daytime Sleepiness in Narcolepsy With Baclofen. ( Kelly-Pieper, K; Kothare, SV; Morse, AM, 2019) |
| " At 100 mg/kg, CGP35348 shifted the dose-response curves of baclofen and SKF97541 to the right but not those of GHB and GBL; at 320 mg/kg, CGP35348 shifted the curves of all four compounds to the right." | 1.34 | Cataleptic effects of gamma-hydroxybutyrate (GHB), its precursor gamma-butyrolactone (GBL), and GABAB receptor agonists in mice: differential antagonism by the GABAB receptor antagonist CGP35348. ( Coop, A; Koek, W; Mercer, SL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morse, AM | 1 |
| Kelly-Pieper, K | 1 |
| Kothare, SV | 1 |
| Carter, LP | 1 |
| Koek, W | 2 |
| France, CP | 1 |
| Huang, YS | 1 |
| Guilleminault, C | 2 |
| Brown, MA | 1 |
| Mercer, SL | 1 |
| Coop, A | 1 |
2 reviews available for baclofen and Gelineau Syndrome
| Article | Year |
|---|---|
Behavioral analyses of GHB: receptor mechanisms.
Topics: Animals; Baclofen; Behavior, Animal; Discrimination Learning; GABA-B Receptor Agonists; Humans; Illi | 2009 |
A review of sodium oxybate and baclofen in the treatment of sleep disorders.
Topics: Animals; Baclofen; GABA-B Receptor Agonists; Humans; Narcolepsy; Sleep; Sleep Initiation and Mainten | 2011 |
1 trial available for baclofen and Gelineau Syndrome
| Article | Year |
|---|---|
Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate.
Topics: Adolescent; Baclofen; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Female; Fo | 2009 |
2 other studies available for baclofen and Gelineau Syndrome
| Article | Year |
|---|---|
Management of Excessive Daytime Sleepiness in Narcolepsy With Baclofen.
Topics: Adolescent; Baclofen; Central Nervous System Depressants; Female; GABA-B Receptor Agonists; Humans; | 2019 |
Cataleptic effects of gamma-hydroxybutyrate (GHB), its precursor gamma-butyrolactone (GBL), and GABAB receptor agonists in mice: differential antagonism by the GABAB receptor antagonist CGP35348.
Topics: 4-Butyrolactone; Animals; Baclofen; Catalepsy; Dose-Response Relationship, Drug; GABA Agonists; GABA | 2007 |